| Formulary Chapter 3: Respiratory system - Full Chapter
|
| 03.04.03 |
Allergic emergencies |
|
|
Adrenaline / epinephrine (Epipen®)
(Auto-injector)
|
First Choice
|
Two injection devices should be prescribed and carried at all times to treat symptoms until medical assistance is available.
NB: Ensure that training is given to all patients, for all prescriptions, irrespective of whether patients have received or used the product previously. Prescribers should specify the brand to be dispensed.
From 1 October 2017 the Human Medicines (Amendment) Regulations 2017 will allow all schools to buy adrenaline auto-injector (AAI) devices without a prescription, for emergency use in children who are at risk of anaphylaxis but their own device is not available or not working (e.g. because it is broken, or out-of-date).
|
Adrenaline / Epinephrine (Emerade®)
|
Non Formulary
|
Two injection devices should be carried at all times to treat symptoms until medical assistance is available.
NB: Ensure that training is given to all patients, for all prescriptions, irrespective of whether patients have received or used the product previously. Prescribers should specify the brand to be dispensed.
From 1 October 2017 the Human Medicines (Amendment) Regulations 2017 will allow all schools to buy adrenaline auto-injector (AAI) devices without a prescription, for emergency use in children who are at risk of anaphylaxis but their own device is not available or not working (e.g. because it is broken, or out-of-date). |
Adrenaline / Epinephrine (Jext®)
|
Non Formulary
|
Two injection devices should be carried at all times to treat symptoms until medical assistance is available.
NB: Ensure that training is given to all patients, for all prescriptions, irrespective of whether patients have received or used the product previously. Prescribers should specify the brand to be dispensed.
From 1 October 2017 the Human Medicines (Amendment) Regulations 2017 will allow all schools to buy adrenaline auto-injector (AAI) devices without a prescription, for emergency use in children who are at risk of anaphylaxis but their own device is not available or not working (e.g. because it is broken, or out-of-date). |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Red: Medicines which should only be prescribed in secondary care by a specialist. |
|
Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred. |
|
Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO). |
|
Green: Medicines which are suitable for initiation and ongoing prescribing within primary care. |
|
Brown: Medicines which should only be prescribed in restricted circumstances. |
|
Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety. |
|
not used |
|
|
